Literature DB >> 1721206

Histopathology of monopolar transcatheter radiofrequency ablation at the mitral valve annulus.

M C Chin1, T Schuenemeyer, W E Finkebeiner, R A Stern, M M Scheinman, J J Langberg.   

Abstract

Although monopolar radiofrequency (RF) catheter ablation is being used to interrupt left-sided accessory pathways in patients with tachyarrhythmia, little is known of the histologic effects from this method of treatment. RF ablation at the mitral valve (MV) annulus was performed in ten dogs to examine the histology of the lesion area. A custom 6 French ablation catheter with a 4 mm distal electrode was positioned beneath the MV adjacent to the annulus. Mean preablation atrial to ventricular electrogram ratio (A/V ratio) was 0.26 +/- 0.17. Thirty +/- 1 watts of RF power were applied for 53 +/- 13 seconds between the distal electrode and a large skin electrode. Nine dogs were sacrificed 6 weeks and one dog 2 days following ablation. Annular lesions were seen in eight of the ten dogs. Lesion volume was 136 +/- 41 mm3 and correlated with the A/V ratio (r2 = 0.74, P = 0.006). Lesions consisted of necrosis of the left ventricle with extension into the atrioventricular groove and left atrium. No injury to the coronary sinus or circumflex artery was observed. A small area of injury was noticed on the mitral leaflet in one dog. Monopolar RF ablation creates lesions at the MV annulus without injury to adjacent vascular structures.

Entities:  

Mesh:

Year:  1991        PMID: 1721206     DOI: 10.1111/j.1540-8159.1991.tb02797.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  1 in total

1.  Prospective assessment after pediatric cardiac ablation: fate of intracardiac structure and function, as assessed by serial echocardiography.

Authors:  George F Van Hare; Steven D Colan; Harold Javitz; Dorit Carmelli; Timothy Knilans; Michael Schaffer; John Kugler; Craig J Byrum; J Philip Saul
Journal:  Am Heart J       Date:  2007-05       Impact factor: 4.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.